Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Challenges for effective treatment and vaccination of respiratory syncytial virus

From: Potential therapeutic implications of new insights into respiratory syncytial virus disease

Prevent RSV bronchiolitis in infants under 6 months:
   Maternal of neonatal vaccination
   Passive antibody administration
Studies are required:
To identify factors that induce Th1 versus Th2 responses
To gain an understanding of tolerance and immune suppression
To gain an understanding the role of nonprotein antigens
To control IgE responses
To boost IgA responses
To make practical improvements to DNA vaccination
To develop new adjuvants
  1. RSV, respiratory syncytial virus; Th, T-helper.